Stanford Researchers Identify AI-Discovered Molecule BRP as Potential Ozempic Alternative

Discovery of BRP

Scientists at Stanford Medicine have identified a naturally occurring molecule called BRP that could lead to a new generation of weight loss medications. Early animal experiments suggest that it can suppress appetite and promote fat loss much like semaglutide, the active ingredient in Ozempic, while potentially avoiding some of the drug's troublesome side effects.

The molecule works differently from existing treatments. Rather than affecting several organs throughout the body, it appears to act more selectively on a part of the brain responsible for controlling hunger and metabolism.

"The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," said assistant professor of pathology Katrin Svensson, PhD. "That's why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."

How AI Uncovered the Molecule

Researchers discovered BRP with the help of artificial intelligence, which allowed them to search through thousands of possible biological compounds. The team created a computer algorithm called Peptide Predictor. Instead of physically isolating and examining hundreds of thousands of peptides, the program analyzed the roughly 20,000 genes that encode human proteins, looking for sequences where an enzyme called prohormone convertase 1/3 was likely to make cuts.

These filters reduced an enormous collection of possibilities to 373 prohormones. Peptide Predictor estimated that the enzyme could produce 2,683 distinct peptides from those 373 proteins. The researchers eventually tested 100 peptides, including GLP-1, using nerve cells grown in the laboratory.

One previously unrecognized peptide, consisting of just 12 amino acids, increased neuronal activity tenfold compared with the controls. The researchers named the molecule BRP after the larger protein from which it originates, BPM/retinoic acid inducible neural specific 2, or BRINP2.

Animal Study Results

The team tested BRP in lean mice and minipigs. Before the animals were fed, researchers administered BRP through an injection into the muscle. During the following hour, the treated animals consumed up to 50% less food than expected.

Obese mice received daily BRP injections for 14 days. By the end of the experiment, the treated mice had lost an average of 3 grams, while untreated control mice had gained approximately 3 grams. Nearly all the weight lost by the BRP-treated mice came from body fat rather than muscle.

The treated animals also showed improvements in glucose and insulin tolerance. The researchers found no significant differences in movement, water consumption, anxiety-related behavior, or fecal output compared with control animals.

Next Steps

Despite the encouraging findings, BRP is still at an early stage of development. Researchers need to understand more about exactly how the molecule communicates with cells and how its effects might be sustained over longer periods. One priority is identifying the cell surface receptors that recognize BRP.

The ultimate challenge will be establishing whether its apparent advantages in animals translate into meaningful benefits for patients. Clinical trials will need to evaluate its safety, effectiveness, appropriate dosage, and potential side effects before it could become a practical obesity treatment.

"The lack of effective drugs to treat obesity in humans has been a problem for decades," Svensson said. "Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."

Why it matters

• BRP reduced food intake by up to 50% in animal tests.
• The molecule promoted fat loss without significant muscle loss in obese mice over 14 days.
• BRP targets the hypothalamus specifically, unlike semaglutide which affects multiple organs.
• Human clinical trials are needed to determine if the results apply to people.

Sources

• sciencedaily.com: AI helps Stanford scientists discover a “natural Ozempic” with a surprising advantage | ScienceDaily
• news.ssbcrack.com: Scientists Discover Promising Molecule for Weight Loss Therapy at Stanford Medicine - SSBCrack News

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.